会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 32. 发明申请
    • LIQUID CRYSTAL DISPLAY DEVICE
    • 液晶显示装置
    • WO1998000475A1
    • 1998-01-08
    • PCT/EP1997003168
    • 1997-06-18
    • MERCK PATENT GMBHHANMER, JamesVERRALL, Mark
    • MERCK PATENT GMBH
    • C09K19/38
    • C09K19/2007C09K19/2014C09K19/38C09K2019/0448G02B5/3016G02F1/13363G02F2001/133638G02F2413/03G02F2413/07G02F2413/15Y10T428/10Y10T428/1059
    • The invention relates to a liquid crystal display device comprising a liquid crystal cell and at least one compensation film or a combination of polarizers and optical compensators comprising at least one compensation film, said compensation film comprising at least one layer of an anisotropic polymer obtainable by (co)polymerization of a mixture of a polymerizable mesogenic material comprising: a) at least one mesogen having at least one polymerizable functional group, in the presence of b) an initiator, c) optionally a non-mesogenic compound having two or more polymerizable functional groups and d) optionally a stabilizer, characterized in that said layer of an anisotropic polymer has a homeotropic or tilted homeotropic molecular orientation. The invention also relates to methods of manufacturing said compensation films. The invention further relates to mixtures of chiral polymerizable mesogenic material used for the manufacturing of said compensation films.
    • 本发明涉及一种液晶显示装置,它包括液晶单元和至少一个补偿膜或包括至少一个补偿膜的偏振器和光学补偿器的组合,所述补偿膜包括至少一层可由( 可聚合的介晶材料的混合物的共聚合,包括:a)至少一个具有至少一个可聚合官能团的介晶,在b)引发剂的存在下,c)任选地具有两个或多个可聚合官能团的非介晶化合物 基团和d)任选的稳定剂,其特征在于所述各向异性聚合物层具有垂直或倾斜的垂直分子取向。 本发明还涉及制造所述补偿膜的方法。 本发明还涉及用于制造所述补偿膜的手性可聚合介晶材料的混合物。
    • 34. 发明申请
    • CYCLIC ADHESION INHIBITORS
    • CYCLIC粘附抑制剂
    • WO1997038009A1
    • 1997-10-16
    • PCT/EP1997001657
    • 1997-04-02
    • MERCK PATENT GMBHJONCZYK, AlfredGOODMAN, SimonDIEFENBACH, BeateKESSLER, HorstKOPPITZ, Marcus
    • MERCK PATENT GMBH
    • C07K07/64
    • C07K7/64A61K38/00C07K14/75
    • The invention concerns cyclopeptides of formula (I): Cyclo-(Arg-Gly-Asp-X-Y) in which X is Cha, Nal, Phe, 2-R -Phe, 3-R -Phe, 4-R -Phe, homo-Phe, Phg, Thi, Trp, Tyr or derivatives of Tyr, whereby the OH group can be etherified by alkyl groups containing 1-18 C-atoms and the amino-acid groups given can also be derivatives, R is NH2, NO2, I, Br, Cl, F, alkyl with 1-18 C-atoms, Ar, Ar-O or H, Y is Gly in which the alpha N-atom may be substituted by R and/or the alpha C-atom may be substituted by R and/or R , with the provision that Gly has at least one of the substituents specified, Ar is phenyl which may be substituted by one or two of the groups NH2, NO2, I, Br, Cl, F, alkyl with 1-6 C-atoms or H, R , R or R , independently of each other, are alkyl with 1-18 C-atoms or R and R or R and R together in each case are a branched or unbranched alkylene chain with 3 to 18 C-atoms so that either the alpha N-atom and the alpha C-atom together with the alkylene chain, or the alpha C-atom alone, forms a ring with the alkylene chain, whereby, when optically active amino-acid or amino-acid-derivative groups are involved, both the D- and the L-form are included, plus derivatives, in particular the beta -ester of aspartic acid or N-guanidine acyl derivatives of arginine or prodrug as well as their physiologically acceptable salts. These compounds act as integrin inhibitors and may be used particularly for the prophylaxis and treatment of circulatory and angiogenic conditions and microbial infections as well as in tumor therapy.
    • 本发明涉及式(I)下式的新的环肽:环 - (精氨酸 - 甘氨酸 - 天冬氨酸-XY)中的X是茶,碘化钠,苯丙氨酸,2-R <1> -Phe,3-R <1> -Phe,4- [R <1> -Phe,同型苯丙氨酸,PHG,氏,色氨酸,酪氨酸或其中OH基团可以被具有1-18个碳原子的烷基基团被醚化的Tyr,的衍生物,以及其中提及的氨基酸残基也另外被衍生 可能; [R <1> NH 2,NO 2,I,溴,氯,F,烷基具有1-18个碳原子中,Ar中,Ar-O或<3> H; Y是甘氨酸,其特征在于,所述α-N-原子由R <2>和/或由R阿尔法-C原子<3>和/或R <4>可以被取代,其条件是至少甘氨酸容易 表明为取代的方式; Ar是苯基,其可以任选地单 - 或二取代的NH 2,NO 2,I,溴,氯,F,具有1-6个C原子的烷基,或<3> H; [R <2>,R <3>或R <4>各自独立地是烷基在每种情况下具有1-18个C原子,或R <2>和R <3>或R <3>和R <4>也一起 是指具有碳原子数为3〜18,有支链或无支链的亚烷基链,以使这些阿尔法 - N-原子和α-C与亚烷基链一起原子,或α-C与亚烷基链形成环单独原子, 其中,如果是光学活性的氨基酸和氨基酸衍生物,无论是D和L形式都包括在内,和衍生物,特别是天冬氨酸酸性β-酯或精氨酸的N-胍酰基衍生物,前药的基团, 和它们的生理学可接受的盐。 这些化合物作为整联蛋白抑制剂,并且可以特别地用于循环的障碍,血管生成病症,微生物感染的预防和治疗以及在肿瘤治疗中使用。
    • 35. 发明申请
    • LIQUID CRYSTALLINE MEDIUM
    • 液晶媒体INES
    • WO1997009395A1
    • 1997-03-13
    • PCT/EP1996003636
    • 1996-08-19
    • MERCK PATENT GMBHTARUMI, KazuakiSCHULER, BrigittePOETSCH, Eike
    • MERCK PATENT GMBH
    • C09K19/34
    • C09K19/3402C09K19/42C09K2019/3422Y10T428/10
    • The invention relates to a liquid crystalline medium based on a mixture of polar compounds of positive dielectric anisotropy, consisting of one or more compounds of general formula (I) in which R is H, an unsubstituted, a simply by CN or CF3 substituted or at least simply an halogen-substituted alkyl or alkenyl radical with 1 to 15 C atoms, where one or more CH2 groups in said radicals may be mutually independently substituted by -O-, -S-, (a), -CO-, -CO-O-, -O-CO- or -O-CO-O- in such a way that O atoms are not directly linked together; Y is F, Cl, halogenated alkyl, alkenyl or alkoxy with 1 to 6 C atoms; and L is H or F.
    • 本发明涉及一种基于具有正介电各向异性的极性化合物,其特征在于的混合物的液晶介质,它包含通式(I)其中R是H,未取代的,由CN或CF 3或单取代的一种或多种化合物 通过其中这些基团中的一个或多个CH 2个基团各自独立地被-O - , - S - ,的(a), - CO-,-CO取代卤素,烷基或具有1至15个碳原子,链烯基至少单取代的 -O - , - O-CO-或-O-CO-O-以这样一种方式,O原子不直接彼此相连接的,Y是F,Cl,卤代烷基,链烯基或烷氧基的碳原子数为1〜6, 且L是<1> H或F.